Harvard University and Kyowa Kirin Enter Strategic Research Alliance financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.
Harvard University and Kyowa Kirin enter strategic research alliance Multiyear collaboration to advance innovation in therapeutics and biomedical technology platforms
Cambridge, Mass. and Tokyo, Japan –
February 25/26, 2021 – Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) announce that they have entered into a strategic research alliance. The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.
Kyowa Kirin is a Japan-based global specialty pharmaceutical company with drug discovery and commercialization capabilities focused in core therapeutic areas of nephrology, oncology, immunology and allergy, and the central nervous system. By creating opportunities for formal scientific collaboration, the alliance will leverage industry insight and drug dev
Harvard University and Kyowa Kirin Enter Strategic Research Alliance apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis
February 18, 2021 GMT
TOKYO (BUSINESS WIRE) Feb 18, 2021
For Medical Media only. Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, announces today that the Phase 2 study of investigational agent KHK4083 in patients with atopic dermatitis has met the primary endpoint.
KHK4083 is a potential first-in-class, anti-OX40 fully human monoclonal antibody for the treatment of autoimmune diseases, including atopic dermatitis. KHK4083 was first discovered by Kyowa Kirin, and is produced with the Company’s patented POTELLIGENT ® defucosylation technology to enhance its antibody dependent cellular cytotox